Zhu Tao, Zheng Ju-Yan, Huang Ling-Ling, Wang Yan-Hong, Yao Di-Fei, Dai Hai-Bin
Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Front Pharmacol. 2023 Feb 23;14:1137151. doi: 10.3389/fphar.2023.1137151. eCollection 2023.
Poly (ADP-ribose) polymerase 1 (PARP1) is a key DNA damage sensor that is recruited to damaged sites after DNA strand breaks to initiate DNA repair. This is achieved by catalyzing attachment of ADP-ribose moieties, which are donated from NAD, on the amino acid residues of itself or other acceptor proteins. PARP inhibitors (PARPi) that inhibit PARP catalytic activity and induce PARP trapping are commonly used for treating -deficient breast and ovarian cancers through synergistic lethality. Unfortunately, resistance to PARPi frequently occurs. In this review, we present the novel substrates and regulators of the PARP1-catalyzed poly (ADP-ribosyl)ation (PARylatison) that have been identified in the last 3 years. The overall aim is the presentation of protein interactions of potential therapeutic intervention for overcoming the resistance to PARPi.
聚(ADP-核糖)聚合酶1(PARP1)是一种关键的DNA损伤传感器,在DNA链断裂后被招募到损伤位点以启动DNA修复。这是通过催化从NAD捐赠的ADP-核糖部分连接到自身或其他受体蛋白的氨基酸残基上来实现的。抑制PARP催化活性并诱导PARP捕获的PARP抑制剂(PARPi)通常通过协同致死作用用于治疗BRCA缺陷型乳腺癌和卵巢癌。不幸的是,对PARPi的耐药性经常出现。在这篇综述中,我们介绍了过去3年中已鉴定出的PARP1催化的聚(ADP-核糖基)化(PARylation)的新底物和调节剂。总体目标是展示潜在治疗干预的蛋白质相互作用,以克服对PARPi的耐药性。